Resource Type

Journal Article 588

Year

2024 2

2023 45

2022 48

2021 47

2020 49

2019 44

2018 41

2017 33

2016 32

2015 31

2014 38

2013 29

2012 16

2011 14

2010 21

2009 23

2008 22

2007 20

2006 7

2005 5

open ︾

Keywords

response surface methodology 9

B-spline 7

Response surface methodology 7

surface 7

surface roughness 5

surface water 5

hepatitis B virus 4

hepatocellular carcinoma 4

photocatalysis 4

surface integrity 4

adsorption 3

Algae 2

B p65 (NF-κ 2

B p65) 2

Biomarkers 2

Membrane fouling 2

Modification 2

Nanoparticle 2

Organic pollutants 2

open ︾

Search scope:

排序: Display mode:

Vaccine therapies for chronic hepatitis B: can we go further?

Yumei Wen, Xuanyi Wang, Bin Wang, Zhenhong Yuan

Frontiers of Medicine 2014, Volume 8, Issue 1,   Pages 17-23 doi: 10.1007/s11684-014-0313-7

Abstract:

Chronic hepatitis B is a major health burden worldwide.antiviral treatment, therapeutic vaccination is a promising new strategy for the control of chronic hepatitisB.On the basis of the major specific and non-specific immune dysregulations and defects in chronic hepatitisB patients, this paper presents the peptide and protein-based, DNA-based, cell-based, and antigen-antibody-based

Keywords: chronic hepatitis B     therapeutic     antigen-antibody complexes     DNA     vaccine    

Preparation, identification, and clinical application of anti-HBs monoclonal antibody that binds both wild-type and immune escape mutant HBsAgs

Fanghe LI BM , Chunyan ZHANG MS , Jinghua LIU MS , Xiaoyan ZHANG MS , Bing YAN , Bo ZHANG MS , Yongguo HUANG MS , Jingsong GONG BM , Yan CHEN BM ,

Frontiers of Medicine 2009, Volume 3, Issue 3,   Pages 277-283 doi: 10.1007/s11684-009-0047-0

Abstract: HBsAg species, which varied in the “a” determinant, in a group of patients infected with hepatitisB virus (HBV).Using the G6 ELISA and two commercial ELISA kits (A and B), 177 patients were tested.

Keywords: hepatitis B virus     gene variation     hepatitis B surface antigen     immune escape     enzyme-linked immunosorbent    

Experimental Studies on Recombinant Hepatitis B Immunogenic Complex Therapeutic Vaccine (YIC)

Wenyu mei,He Lifang,Qu Di,Ma Zhangmei,Yao Xin

Strategic Study of CAE 1999, Volume 1, Issue 1,   Pages 38-42

Abstract:

A therapeutic vaccine composed of HBsAg complexed to anti-HBs (IC) has been developed for viral hepatitisB.In addi-tion, this complex was used to immunize an HBsAg low-responder mouse strain (B10.S).Data showed that this immunogenic complex has promising potential to be used for the treatment of hepatitisB patients.

Keywords: hepatitis B     therapeutic vaccine     antigen-antibody complex     immune responses    

Current hepatitis B treatment guidelines and future research directions

Jonathan Skupsky,Ke-Qin Hu

Frontiers of Medicine 2014, Volume 8, Issue 2,   Pages 145-157 doi: 10.1007/s11684-014-0335-1

Abstract:

Hepatitis B virus (HBV) infection causes a tremendous clinical burden across the world with more than

Keywords: chronic hepatitis B     HBV treatment guidelines     APASL guidelines     EASL guidelines     AASLD guidelines    

Clinical characteristics and risk factors of COVID-19 patients with chronic hepatitis B: a multi-center

Frontiers of Medicine 2022, Volume 16, Issue 1,   Pages 111-125 doi: 10.1007/s11684-021-0854-5

Abstract: in COVID-19 patients, the association of liver injury caused by specific subtype especially chronic hepatitisB (CHB) with COVID-19 has not been elucidated.

Keywords: COVID-19     chronic hepatitis B     liver injury     coagulation dysfunction    

Chronic hepatitis B virus infection: epidemiology, prevention, and treatment in China

Rui Yu,Rong Fan,Jinlin Hou

Frontiers of Medicine 2014, Volume 8, Issue 2,   Pages 135-144 doi: 10.1007/s11684-014-0331-5

Abstract:

Chronic hepatitis B is a major health problem in China.The universal vaccination program since 1992 has changed the epidemiology of hepatitis B virus infectionThe most prevalent hepatitis B virus strains in China are genotypes B and C, whereas those in westernChronic hepatitis B poses a heavy burden to the society in China.

Keywords: chronic hepatitis B     epidemiology     prevention     treatment    

Comprehensive treatment of acute-on-chronic liver failure in a patient with hepatitis B: a case report

Lei Li,Yimei Liu,Tiancheng Luo,Jian Zhou,Yingyong Hou,Xizhong Shen,Jiyao Wang

Frontiers of Medicine 2014, Volume 8, Issue 2,   Pages 250-253 doi: 10.1007/s11684-014-0333-3

Abstract: The patient has suffered from hepatitis B for 30 years.Comprehensive treatments included effective inhibition of hepatitis B virus replication and intensive

Keywords: acute-on-chronic liver failure     submassive necrosis     viral hepatitis B     esophageal variceal bleeding     liver    

Correlation between viral load and liver cirrhosis in chronic hepatitis B patients

Lili LIU MM , Jiyao WANG MD , Weimin SHE MM ,

Frontiers of Medicine 2009, Volume 3, Issue 3,   Pages 271-276 doi: 10.1007/s11684-009-0054-1

Abstract: The aim of this paper is to investigate the relationship between hepatitis B virus (HBV) DNA levels duringthe course and the progression to cirrhosis with chronic hepatitis B.A total of 239 chronic hepatitis B patients confirmed by liver biopsy between 2001 and 2007 were followedB e antigen, and γ-glutamyl transpeptidase at baseline were independent risk factors of cirrhosisProgression to cirrhosis in chronic hepatitis B patients is correlated with HBV-DNA levels during follow-up

Keywords: hepatitis B     chronic     viral load     liver cirrhosis    

MicroRNAs and hepatitis viruses

Gang LI MD , Xiaojia XIONG MM ,

Frontiers of Medicine 2009, Volume 3, Issue 3,   Pages 265-270 doi: 10.1007/s11684-009-0055-0

Abstract: years, investigators gradually brought the concept of miRNA into studies of viral infection, including hepatitisThe hepatitis B and C viruses are common causes of liver disease worldwide.It is very difficult to cure chronic hepatitis due to drug resistance during antivirus therapy.Elucidating the mechanisms of virus-host interactions in hepatitis B and C is very important in diagnosisThis article reviews the current knowledge of viral hepatitis (B and C type) at the level of miRNA and

Keywords: microRNA     hepatitis B virus     hepatitis C virus    

Current advances in the elimination of hepatitis B in China by 2030

Shuye Zhang, Fusheng Wang, Zheng Zhang

Frontiers of Medicine 2017, Volume 11, Issue 4,   Pages 490-501 doi: 10.1007/s11684-017-0598-4

Abstract:

With its 78 million chronic carriers, hepatitis B virus (HBV) infection is still one of the leadingefficacious in suppressing HBV replication; however, it fails to completely cure patients with chronic hepatitisB and even requires lifelong treatment.Work is still needed to eliminate hepatitis B in China by 2030.

Keywords: HBV     CHB     biomarker     functional cure     coinfection    

Potential use of serum HBV RNA in antiviral therapy for chronic hepatitis B in the era of nucleos(t)ide

Fengmin Lu, Jie Wang, Xiangmei Chen, Dongping Xu, Ningshao Xia

Frontiers of Medicine 2017, Volume 11, Issue 4,   Pages 502-508 doi: 10.1007/s11684-017-0590-z

Abstract:

Although the efficacy of nucleos(t)ide analogue (NA) has been confirmed for treatment of chronic hepatitisB, long-term therapy has been recommended due to the high frequency of off-therapy viral DNA reboundIn this review, the RNA virion-like particles of hepatitis B virus (HBV) are integrated into the lifeIn contrast to hepatitis B surface antigen (HBsAg) that can originate from either the cccDNA or the integratedB, to distinguish the “functional cure” characterized as serum HBsAg loss with or without

Keywords: chronic hepatitis B     serum HBV RNA     nucleos(t)ide analogs     virological response     para-functional cure    

New perspective on the natural course of chronic HBV infection

Yong-Yuan Zhang,Ke-Qin Hu,Zhongping Duan

Frontiers of Medicine 2014, Volume 8, Issue 2,   Pages 129-134 doi: 10.1007/s11684-014-0339-x

Abstract:

Chronic hepatitis B virus (HBV) infection is a significant threat to public health and an enormousHBV infection is conventionally viewed as an uninterrupted process that is usually marked by HBV e antigenmutant becomes predominant in the viral population following elimination of the wild-type virus in duck hepatitisB virus-chronically infected animals.

Keywords: hepatitis B virus     chronic HBV infection     natural course     hepatitis B     seroconversion    

Association of novel mutations and heplotypes in the preS region of hepatitis B virus with hepatocellular

Jia-Xin XIE, Jian-Hua YIN, Qi ZHANG, Rui PU, Wen-Ying LU, Hong-Wei ZHANG, Guang-Wen CAO, Jun ZHAO, Hong-Yang WANG,

Frontiers of Medicine 2010, Volume 4, Issue 4,   Pages 419-429 doi: 10.1007/s11684-010-0160-0

Abstract: The association of viral mutations and haplotypic carriages with mutations in the preS region of hepatitisB virus (HBV) genotypes B and C with hepatocellular carcinoma (HCC) is of great significance for theWe analyzed the preS sequences of HBV genotypes B and C from 1172 HBV-infected subjects including 231risks of HCC in genotype C, whereas these mutations were inversely associated with HCC in genotype B.

Keywords: hepatitis B virus     hepatocellular carcinoma     mutation     genotype     haplotype    

Association of miRNA-122-binding site polymorphism at the interleukin-1 α gene and its interaction with hepatitisB virus mutations with hepatocellular carcinoma risk

Du Yan, Han Xue, Pu Rui, Xie Jiaxin, Zhang Yuwei, Cao Guangwen

Frontiers of Medicine 2014, Volume 8, Issue 2,   Pages 217-226 doi: 10.1007/s11684-014-0326-2

Abstract: binding site polymorphism at the IL-1A gene and its multiplicative interactions with hepatitisB virus (HBV) mutations in the risk of hepatocellular carcinoma (HCC).A total of 1021 healthy controls, 302 HBV surface antigen (HBsAg) seroclearance subjects, and 2011 HBsAg-positiveAdditionally, rs3783553 was not significantly associated with chronic HBV infection, liver cirrhosis, HBV e antigen

Keywords: hepatocellular carcinoma (HCC)     interaction     miRNA-122-binding site     IL-1A     rs3783553     hepatitis B virus (    

Phase I study of CBM.CD19 chimeric antigen receptor T cell in the treatment of refractory diffuse largeB-cell lymphoma in Chinese patients

Frontiers of Medicine 2022, Volume 16, Issue 2,   Pages 285-294 doi: 10.1007/s11684-021-0843-8

Abstract: Anti-CD19 chimeric antigen receptor (CAR) T cell therapy has shown impressive efficacy in treating B-cellCAR bearing 4-1BB costimulatory molecule, for the treatment of patients with refractory diffuse large B-cell

Keywords: CAR-T cell therapy     refractory diffuse large B-cell lymphoma     cytokine release syndrome     dose-limiting    

Title Author Date Type Operation

Vaccine therapies for chronic hepatitis B: can we go further?

Yumei Wen, Xuanyi Wang, Bin Wang, Zhenhong Yuan

Journal Article

Preparation, identification, and clinical application of anti-HBs monoclonal antibody that binds both wild-type and immune escape mutant HBsAgs

Fanghe LI BM , Chunyan ZHANG MS , Jinghua LIU MS , Xiaoyan ZHANG MS , Bing YAN , Bo ZHANG MS , Yongguo HUANG MS , Jingsong GONG BM , Yan CHEN BM ,

Journal Article

Experimental Studies on Recombinant Hepatitis B Immunogenic Complex Therapeutic Vaccine (YIC)

Wenyu mei,He Lifang,Qu Di,Ma Zhangmei,Yao Xin

Journal Article

Current hepatitis B treatment guidelines and future research directions

Jonathan Skupsky,Ke-Qin Hu

Journal Article

Clinical characteristics and risk factors of COVID-19 patients with chronic hepatitis B: a multi-center

Journal Article

Chronic hepatitis B virus infection: epidemiology, prevention, and treatment in China

Rui Yu,Rong Fan,Jinlin Hou

Journal Article

Comprehensive treatment of acute-on-chronic liver failure in a patient with hepatitis B: a case report

Lei Li,Yimei Liu,Tiancheng Luo,Jian Zhou,Yingyong Hou,Xizhong Shen,Jiyao Wang

Journal Article

Correlation between viral load and liver cirrhosis in chronic hepatitis B patients

Lili LIU MM , Jiyao WANG MD , Weimin SHE MM ,

Journal Article

MicroRNAs and hepatitis viruses

Gang LI MD , Xiaojia XIONG MM ,

Journal Article

Current advances in the elimination of hepatitis B in China by 2030

Shuye Zhang, Fusheng Wang, Zheng Zhang

Journal Article

Potential use of serum HBV RNA in antiviral therapy for chronic hepatitis B in the era of nucleos(t)ide

Fengmin Lu, Jie Wang, Xiangmei Chen, Dongping Xu, Ningshao Xia

Journal Article

New perspective on the natural course of chronic HBV infection

Yong-Yuan Zhang,Ke-Qin Hu,Zhongping Duan

Journal Article

Association of novel mutations and heplotypes in the preS region of hepatitis B virus with hepatocellular

Jia-Xin XIE, Jian-Hua YIN, Qi ZHANG, Rui PU, Wen-Ying LU, Hong-Wei ZHANG, Guang-Wen CAO, Jun ZHAO, Hong-Yang WANG,

Journal Article

Association of miRNA-122-binding site polymorphism at the interleukin-1 α gene and its interaction with hepatitisB virus mutations with hepatocellular carcinoma risk

Du Yan, Han Xue, Pu Rui, Xie Jiaxin, Zhang Yuwei, Cao Guangwen

Journal Article

Phase I study of CBM.CD19 chimeric antigen receptor T cell in the treatment of refractory diffuse largeB-cell lymphoma in Chinese patients

Journal Article